Mode
Text Size
Log in / Sign up

Meta-analysis compares endoscopic transorbital and transcranial approaches for spheno-orbital meningioma

Meta-analysis compares endoscopic transorbital and transcranial approaches for spheno-orbital…
Photo by CDC / Unsplash
Key Takeaway
Consider ETOA for proptosis improvement but recognize lower GTR rates and shorter follow-up compared to transcranial approaches.

This meta-analysis of observational studies pooled data from 2016 patients with spheno-orbital meningiomas to compare the endoscopic transorbital approach (ETOA) with standard transcranial approaches. The analysis focused on improvement in proptosis and visual function, extent of resection, and complications.

Key findings: Proptosis improvement favored ETOA (96% vs 72%), but gross total resection (GTR) was significantly lower with ETOA (21.1% vs 48.0%; OR 5.00 favoring transcranial after sensitivity analysis, p=0.047). Visual improvement showed no significant difference (31% vs 33%, p=0.857). Complication rates were similar (18% vs 26%, p=0.165). Recurrence and progression appeared lower after ETOA, but this was likely confounded by shorter follow-up (median 18 months for ETOA vs 52 months for transcranial).

Limitations include the observational nature of included studies, heterogeneity, and significant differences in follow-up duration. The lower GTR rate with ETOA and potential confounding of recurrence data by follow-up time are important caveats.

Practice relevance: ETOA is a valid surgical strategy for appropriately selected patients, but transcranial approaches remain the workhorse for cases requiring extensive intracranial or dural control. These findings should be interpreted cautiously given the lack of adjusted comparisons and the observational evidence base.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BackgroundSpheno-orbital meningiomas (SOMs) are challenging skull base tumors requiring a balance between oncologic control and functional–aesthetic outcomes. Endoscopic transorbital approaches (ETOA) have recently gained popularity as minimally invasive alternatives to standard transcranial techniques, but comparative evidence is lacking.MethodsA systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed/MEDLINE, Embase, and Scopus were searched from inception to the final search date. Studies reporting outcomes after ETOA or standard transcranial approaches were included. Primary outcomes included improvement in proptosis and visual function, extent of resection, and complications. Secondary outcomes included tumor progression and recurrence. Random-effects generalized linear mixed models were used to pool proportions. Mixed-effects meta-regression evaluated the association between approach and outcomes.ResultsFifty-three studies encompassing 2016 patients were included. A total of 155 (7.7%) ETOA and 1864 (92.3%) transcranial approaches were performed. Proptosis improvement was greater with ETOA (96% vs 72%) while visual improvement was similar (ETOA 31% vs standard 33%; p=0.857). Gross total resection (GTR) was lower with ETOA (21.1% vs 48.0%) and favored transcranial approaches after sensitivity analysis excluding influential studies (OR 5.00, p=0.047). Complication rates did not differ significantly between approaches, with a numerically lower rate observed after ETOA compared with standard transcranial surgery (18% vs 26%; p = 0.165). Median follow-up was shorter in the ETOA series (18 vs 52 months); recurrence and progression were lower after ETOA but likely influenced by follow-up duration.ConclusionsETOA demonstrates superior proptosis improvement compared with standard transcranial approaches, comparable visual outcomes, and lower rates of GTR. Complication rates did not differ significantly. In appropriately selected SOMs, ETOA represents a valid surgical strategy within a tailored, goal-oriented approach, while standard transcranial techniques remain a workhorse for cases requiring extensive intracranial or dural control. Longer follow-up is required to clarify long-term tumor control.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.